Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ankyrin Repeat Domain 1, ANKRD1, a Novel Determinant of Cisplatin Sensitivity Expressed in Ovarian Cancer

1 Nov 2008

Abstract excerpt

PURPOSE: The standard of care for ovarian cancer includes platinum-based chemotherapy. It is not possible, however, to predict clinical platinum sensitivity or to design rational strategies to overcome resistance. We used a novel approach to identify altered gene expression associated with high sensitivity to cisplatin, to define novel targets to sensitize tumor cells to platins and ultimately improve the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell death mechanisms and regulation
Share to Ferroptosis and cancer prognosis
Share to Microtubule and mitosis dynamics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18980987
DOI: 10.1158/1078-0432.ccr-07-5189

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ankyrin Repeat Domain 1, ANKRD1, a Novel Determinant of Cisplatin Sensitivity Expressed in Ovarian CancerPMID 18980987Read ↗

Identification of Three Potential Prognostic Genes in Platinum-Resistant Ovarian Cancer via Integrated Bioinformatics AnalysisSemantic proximity Read ↗

Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780Semantic proximity Read ↗

Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cellsSemantic proximity Read ↗

Suppression of <i>ABHD2</i>, identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancerSemantic proximity Read ↗

Comprehensive analysis of hub genes associated with cisplatin-resistance in ovarian cancer and screening of therapeutic drugs through bioinformatics and experimental validationSemantic proximity Read ↗

Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells.Semantic proximity Read ↗

Inhibition of ANKRD1 sensitizes human ovarian cancer cells to endoplasmic reticulum stress-induced apoptosisSemantic proximity Read ↗

Molecular profiling of platinum resistant ovarian cancerSemantic proximity Read ↗

Cisplatin Resistant Spheroids Model Clinically Relevant Survival Mechanisms in Ovarian TumorsSemantic proximity Read ↗

Mitochondrial Proteomic Analysis of Cisplatin Resistance in Ovarian CancerSemantic proximity Read ↗

Tyrosine kinase receptor TIE-1 mediates platinum resistance by promoting nucleotide excision repair in ovarian cancerSemantic proximity Read ↗

Altered ErbB Receptor Signaling and Gene Expression in Cisplatin-Resistant Ovarian CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.